

**Remarks**

Applicants have amended the specification to provide the priority claim. Claims 8-10 have been amended to remove multiple dependencies and to otherwise place the claims in an appropriate U.S. format. Claims 6-7 have been cancelled without prejudice. New claim 15 has been added. The support for claim 15 can be found at line 7, page 11 of the original specification. No new matter has been added by these amendments.

Applicants believe the application is in condition for allowance, which action is respectfully requested.

Although Applicants believe no fees are due, the Commissioner is hereby authorized to charge any deficiency in the fees or credit any overpayment to deposit account No. 26-0166, referencing Attorney Docket No. 101258-1P US.

Respectfully submitted,  
/Jianzhong SHEN, Reg.#48076/

---

Name: Jianzhong Shen  
Dated: June 27, 2006  
Reg. No.: 48,076  
Phone No.: 302-886-8854  
Global Intellectual Property, Patents,  
AstraZeneca,  
1800 Concord Pike,  
Wilmington,  
DE-19850-5437